Use of abatacept in rheumatoid arthritis: Recommendations based on current evidence

Swiss Medical Weekly

Volumn 142, Issue MAY, 2012, Pages

  Von Kempis, Johannes ^a   Dudler, Jean ^b   Hasler, Paul ^c   Kyburz, Diego ^d   Tyndall, Alan ^e   Zufferey, Pascal ^f   Villiger, Peter M ^g  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Hopital Cantonal de Fribourg   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

Abatacept; Recommendations; Rheumatoid arthritis; Therapy; Use

Indexed keywords

ABATACEPT; ANTINUCLEAR ANTIBODY; DNA ANTIBODY; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INFLUENZA VACCINE; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPATHOGENESIS; INFUSION RELATED REACTION; JOINT DESTRUCTION; LUNG CANCER; LYMPHOMA; MAINTENANCE THERAPY; NON MELANOMA SKIN CANCER; NONHUMAN; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREGNANCY; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; T LYMPHOCYTE; TUBERCULOSIS; URINARY TRACT INFECTION;

EID: 84863487145     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13581     Document Type: Review

References (30)

1. Choy EH. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(3):510-8.
2. Orencia® (Abatacept): Swiss prescribing information for physicians.
3. Pettit AR, Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis? Immunol Cell Biol. 1999;77(5):420-7. (Pubitemid 29476912)
4. Janeway C. Immunobiology: The immune system in health and disease. 6th ed, New York: Garland Science Publishing. 2005:319-65; 557-612.
5. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009;68(7):1220-7.
6. Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33(11):2162-6. (Pubitemid 44749773)
7. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexatenaive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870-7.
8. Westhovens R, Durez P, Genant H, Robles M, Becker JC, Covucci A, et al. Disease remission, normalized physical function and radiographic non-progression are achieved by the majority of patients with early rheumatoid arthritis treated with abatacept + methotrexate: results from the 2-year AGREE trial. Poster SAT0178, EULAR Annual Congress, June 16-19, 2010.
9. Keystone E, Westhovens R, Moniz Reed D, Covucci A, Wells A. Radiographic progression correlates well with patient-reported RAPID3 disease activity levels in methotrexate (MTX).naive patients with early rheumatoid arthritis (RA): insights from the AGREE study. Arthritis & Rheumatism. 2010;62(10 Suppl):S470.
10. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865-76. (Pubitemid 46768126)
11. Dougados M, Kremer JM, Le Bars M, Reed D, Park S, Vatsanos G, et al. Abatacept improves disease activity status over time in patients with rheumatoid arthritis and an inadequate response to methotrexate [abstract]. Ann Rheum Dis. 2009;68:573.
12. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, doubleblind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096-103.
13. Genant HK, Peterfy C, Westhovens R, Becker JC, Vratsanos G, Zhou X, et al. Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with rheumatoid arthritis. Poster FRI0253, EULAR Annual Congress, June 10-13, 2009.
14. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-23. (Pubitemid 41317434)
15. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-23. (Pubitemid 41317434)
16. Schiff M, Keiserman MW, Moniz Reed D, Le Bars M, Becker J-C, Zhao C, et al. An increasing proportion of patients achieve a low disease activity state or remission when switched from infliximab to abatacept regardless of initial infliximab treatment response: results from the ATTEST trial. Poster 1659 (392), ACR/ARHP Annual Scientific Meeting, October 16-21, 2009.
17. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708-14.
18. Durez P, Bathon J, Becker JC, Covucci A, Moniz Reed D, Westhovens R. Time course of improvement in ACR core components in patients with early rheumatoid arthritis treated with abatacept plus methotrexate. Poster FRI0201, EULAR Annual Congress, June 16-19, 2010.
19. Westhovens R, Moniz Reed D, Becker J-C, Vratsanos G, Yazici Y. Early improvements in disease activity with abatacept continue to increase or are maintained over time in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Poster SAT0109. EULAR Congress, 10-13 June, 2009.
20. Westhovens R, Dougados M, Hall S, Moniz Reed D, Becker J-C, Teng J, et al. Disease remission, radiographic non-progression and normalization of function achieved at year 1 are sustained long-term in a majority of patients: 5-year outcomes with abatacept in biologic-naïve patients. Poster 1657 (390). ACR/ARHP Annual Scientific Meeting, October 16-21, 2009.
21. Hochberg MH, Westhovens R, Aranda R, Kelly S, Khan N, Qi K, et al. Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment. Poster 390, ACR/ARHP Annual Scientific Meeting, November 7-11, 2010.
22. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). The Cochrane Library. 2011, Issue 2.
23. Smitten A, Westhovens R, Hochberg M, Torbeyns A, Becker J-C, Aranda R. Serious infections and malignancies during long-term exposure to abatacept. Poster SAT0163, EULAR Annual Congress, June 16-19, 2010.
24. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66:228-34. (Pubitemid 46226059)
25. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Research & Therapy. 2007;9:R38.
26. Schiff M, Saewert M, Bahrt K, Genovese MC. Response to influenza vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial. Poster FRI 943/175, ACR Congress, November 6-11, 2007.
27. Ribeiro A, Guedes L, Moraes J, Saad C, Calich A, Aikawa N, et al. Abatacept in association with traditional DMARDS severely impairs humoral response to pandemic A H1N1 influenza vaccination in rheumatoid arthritis patients. Ann Rheum Dis. 2011;70(Suppl3):458. Abstract FRI0342.
28. Schiff M, Kaell A, Tay L, Vratsanos G, Bahrt K. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial. Poster SAT0029, EULAR, June 13-16, 2007.
29. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Incidence of anti-nuclear and anti-DNA antibody seropositivity, and immunogenicity, in patients with rheumatoid arthritis treated with abatacept or infliximab. Poster SAT0030, EULAR, June 13-16, 2007.
30. Jean Dudler, Burkhard Möller, Beat A. Michel, Peter M. Villiger. Biologics in rheumatoid arthritis (RA) - recommendations for Swiss practice. Swiss Med Wkly. 2011;141:w13189.